Relationship Between Pimavanserin Exposure and Negative Symptoms in Patients With Schizophrenia: Data Analysis From the Phase 2 ADVANCE Study

Conference: ASCP
Division: Cognigen


• Negative symptoms in schizophrenia are associated with poor psychosocial function and long-term outcomes yet no pharmacological treatments are currently approved in the United States to treat negative symptoms.
• Pimavanserin is a selective serotonin receptor-modulating agent with inverse agonist/antagonist activity at 5-HT2A receptors and to a lesser extent at 5-HT2C receptors.
• Pimavanserin is being investigated in negative symptoms of schizophrenia.
• Exposure–response (E–R) analyses can be useful to help determine an optimal dose and to support clinical evidence of efficacy.

By, Mona Darwish, Dragana Bugarski-Kirola, Julie Passarell, Mark Forman, Daryl DeKarske, David Jaworowicz, Joel Owen, Srdjan Stankovic.

Poster presented at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, June 1-4, 2021; Virtual.